Clinical Trials Directory

Trials / Unknown

UnknownNCT06016010

Efficacy and Safety of USL for Dry Eye Disease

Efficacy and Safety of USL for Dry Eye Disease (DED): a Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Clinical Trial

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Chan-Sik Kim · Other Government
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The objective is to compare the USL and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Detailed description

This study is a phase 2, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of USL compared with placebo. A total of 120 patients, aged over 19 years, with Corneal staining score(Oxford grading) ≥ 2 or TBUT \< 10 sec and OSDI ≥ 10 points will be recruited at Daejeon University Daejeon Korean Medicine Hospital. Patients will take medications two times daily for 12 weeks, with 5 visiting days(screening, week 0, week 6, week 12, week 14).

Conditions

Interventions

TypeNameDescription
DRUGUSL500mg of Achyranthis Radix Extract
DRUGUSL PlaceboUSL Placebo

Timeline

Start date
2024-01-01
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2023-08-29
Last updated
2023-09-11

Source: ClinicalTrials.gov record NCT06016010. Inclusion in this directory is not an endorsement.